Altimmune to present pemvidutide clinical data at upcoming american diabetes association scientific sessions june 6, 2022

Gaithersburg, md., may 31, 2022 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced that dr. samuel klein, william h. danforth professor of medicine and nutritional science director, washington university school of medicine, will deliver an oral presentation at the 82nd american diabetes association (ada) scientific sessions, to be held in new orleans, la on june 3-7, 2022. dr. klein will present the results of altimmune's recently completed phase 1, first-in-human clinical trial of pemvidutide, an investigational glp-1/glucagon dual receptor agonist in development for the treatment of obesity and nash.
ALT Ratings Summary
ALT Quant Ranking